This triple-agonist mechanism is unlike older treatments, which generally focus on a single pathway
Gastrointestinal adverse events associated with GLP-1 RAs in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis
Any dosing and pricing are confirmed in person after your evaluation, never quoted as a fixed number online, and financing is available
Unwanted effects could be mild to severe, depending on the dosage
One of MOTS-C's downstream effects is increasing intracellular NAD+ utilization the mitochondria are running harder, so they're consuming more of the NAD+ pool
However, it is banned by the World Anti-Doping Agency (WADA) for Olympic, professional, and championship-level athletes due to its performance-enhancing potential